Top Healthcare stocks:
Healthcare shares were mixed in pre-market trade on Monday.
In healthcare stocks news, Allergan (
) said it still considers Valeant Pharmaceutical International's
(VRX, VRX.TO) business model to be unsustainable and that the
$72-per share and 0.83 Valeant stock offer creates "significant
risks and uncertainties for Allergan shareholders."
Allergan said Valeant's business model relies on "serial
acquisitions and cost reductions, as opposed to top-line revenue
growth and operational excellence."
And, Gilead Sciences, Inc. (
) shares were up slightly after it reported topline results from a
Phase 3 clinical trial in Japan evaluating the investigational
once-daily fixed-dose combination for the treatment of genotype 1
chronic hepatitis C virus infection.
GILD trades in a 52-week range of $46.70 to $84.88.
Also, Response Genetics (
) which is focused on the development and sale of molecular
diagnostic tests that help guide cancer therapy selection,
announced new testing capabilities to advance cancer immunotherapy
RGDX was steady pre-market, having closed up 2.8% at $0.91.
Finally, Cephid (
) said early Monday it has released Xpert Carba-R, an on-demand
molecular test for rapid and accurate detection of
carbapenemase-producing Gram-negative bacteria, to be marketed as a
CE IVD product under the European Directive on In Vitro Diagnostic
Copyright (C) 2014 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.